Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy

The severe neuromuscular disease affects approximately 2,500 people in the UK

- PMLiVE

Axsome announces positive results from phase 3 Alzheimer’s disease programme

The neurodegenerative disease affects approximately seven million people in the US

- PMLiVE

Sanofi and SK bioscience expand pneumococcal vaccine collaboration

The partners’ 21-valent paediatric vaccine entered late-stage clinical development last month

- PMLiVE

Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

There is currently no national screening programme for prostate cancer in the UK

- PMLiVE

Publicis Health appoints Annabelle Sandeman as chief growth officer in UK

Sandeman previously served as global head of commercial strategy at Huntsworth Health, now Inizio

- PMLiVE

Roche gains rights to Innovent Biologics’ ADC candidate in deal worth over $1bn

IBI3009 targets an antigen significantly overexpressed in cancers including small cell lung cancer

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval

Opdivo Qvantig can be administered in three to five minutes compared to 30 minutes for the drug’s IV form

- PMLiVE

J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal

The inflammatory skin disorder affects more than 9.6 million children and 16.5 million adults in the US

- PMLiVE

Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults

SCLC accounts for approximately 15% of all lung cancer diagnoses and progresses rapidly

- PMLiVE

BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

Approximately 27,000 cases of the disease were diagnosed in the US in 2024

- PMLiVE

Novartis’ investigational spinal muscular atrophy gene therapy shows promise in late-stage study

An estimated one in 10,000 infants globally are affected by the rare neuromuscular disease

- PMLiVE

J&J’s Rybrevant/Lazcluze combination approved by EC for EGFR-mutated lung cancer

Alterations in EGFR are among the most common driver mutations in NSCLC patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links